Novel insights into the function of β-cell M3 muscarinic acetylcholine receptors: Therapeutic implications

Trends in Endocrinology and Metabolism

Volumn 22, Issue 2, 2011, Pages 74-80

  Azua, Inigo Ruiz de ^a   Gautam, Dinesh ^a   Guettier, Jean Marc ^a   Wess, Jürgen ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANKYRIN; ANKYRIN B; BETA ARRESTIN 1; BETA ARRESTIN 2; BETHANECHOL; CALCIUM; CLOZAPINE; CLOZAPINE N OXIDE; DIACYLGLYCEROL; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; INOSITOL 1,4,5 TRISPHOSPHATE; INSULIN; INSULIN RECEPTOR SUBSTRATE 2; MUSCARINIC AGENT; MUSCARINIC M3 RECEPTOR; OLANZAPINE; PHOSPHOLIPASE C BETA; PROTEIN INHIBITOR; PROTEIN KINASE D; PROTEIN KINASE D1; RGS PROTEIN; RGS4 PROTEIN; SODIUM ION; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL FUNCTION; DOSE RESPONSE; DOWNSTREAM PROCESSING; DRUG EFFECT; DRUG TARGETING; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; LIPID DIET; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; POINT MUTATION; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SODIUM CURRENT;

ANIMALS; BLOOD GLUCOSE; GTP-BINDING PROTEINS; HOMEOSTASIS; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MICE; MICE, KNOCKOUT; MICE, MUTANT STRAINS; MUTATION; RECEPTOR, MUSCARINIC M3; RGS PROTEINS; SIGNAL TRANSDUCTION;

EID: 79251626567     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2010.10.004     Document Type: Review

References (49)

1. Kahn S.E. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003, 46:3-19.
2. Ahrén B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat. Rev. Drug. Discov. 2009, 8:369-385.
3. Doyle M.E., Egan J.M. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol. Ther. 2007, 113:546-593.
4. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
5. i in vivo identifies GPCR regulators of insulin secretion. J. Clin. Invest. 2007, 117:4034-4043.
6. Ahrén B. Autonomic regulation of islet hormone secretion-implications for health and disease. Diabetologia 2000, 43:393-410.
7. Gilon P., Henquin J.C. Mechanisms and physiological significance of the cholinergic control of pancreatic β-cell function. Endocr. Rev. 2001, 22:565-604.
8. 3 muscarinic acetylcholine receptor-deficient mice. Diabetes 2004, 53:1714-1720.
9. Zawalich W.S., et al. Effects of muscarinic receptor type 3 knockout on mouse islet secretory responses. Biochem. Biophys. Res. Commun. 2004, 315:872-876.
10. Henquin J.C., Nenquin M. The muscarinic receptor subtype in mouse pancreatic B-cells. FEBS Lett. 1988, 236:89-92.
11. Wess J. Molecular biology of muscarinic acetylcholine receptors. Crit. Rev. Neurobiol. 1996, 10:69-99.
12. 3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. Cell Metab. 2006, 3:449-461.
13. + current by muscarinic receptors in mouse pancreatic β-cells. J. Biol. Chem. 2002, 277:38373-38380.
14. Swayne L.A., et al. The NALCN ion channel is activated by M3 muscarinic receptors in a pancreatic β-cell line. EMBO Rep. 2009, 10:873-880.
15. 3 muscarinic acetylcholine receptors in transgenic mice. Endocrinology 2010, 151:5185-5194.
16. 3 receptor and greatly impair receptor/G protein coupling. J. Biol. Chem. 2003, 278:30248-30260.
17. Zawalich W.S., Zawalich K.C. Species differences in the induction of time-dependent potentiation of insulin secretion. Endocrinology 1996, 137:1664-1669.
18. Conn P.J., et al. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol. Sci. 2009, 30:148-155.
19. Caulfield M.P., Birdsall N.J.M. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev 1998, 50:279-290.
20. Wess J., et al. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat. Rev. Drug Discov. 2007, 6:721-733.
21. Ruiz de Azua I., et al. RGS4 is a negative regulator of insulin release from pancreatic β-cells in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:7999-8004.
22. van Koppen C.J., Kaiser B. Regulation of muscarinic acetylcholine receptor signaling. Pharmacol. Ther. 2003, 98:197-220.
23. Ross E.M., Wilkie T.M. GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annu. Rev. Biochem. 2000, 69:795-827.
24. Abramow-Newerly M., et al. RGS proteins have a signalling complex: interactions between RGS proteins and GPCRs, effectors, and auxiliary proteins. Cell Signal. 2006, 18:579-591.
25. Neitzel K.L., Hepler J.R. Cellular mechanisms that determine selective RGS protein regulation of G protein-coupled receptor signaling. Semin. Cell Dev. Biol. 2006, 17:383-389.
26. Bansal G., et al. R4 RGS proteins: regulation of G-protein signaling and beyond. Pharmacol. Ther. 2007, 116:473-495.
27. Cifelli C., et al. RGS4 regulates parasympathetic signaling and heart rate control in the sinoatrial node. Circ. Res. 2008, 103:527-535.
28. Siedlecki A., et al. RGS4 controls renal blood flow and inhibits cyclosporine-mediated nephrotoxicity. Am. J. Transplant. 2010, 10:231-241.
29. Iankova I., et al. Regulator of G protein signaling-4 controls fatty acid and glucose homeostasis. Endocrinology 2008, 149:5706-5712.
30. Xie Y., et al. Breast cancer migration and invasion depend on proteasome degradation of regulator of G-protein signaling 4. Cancer Res. 2009, 69:5743-5751.
31. Erdely H.A., et al. Regional expression of RGS4 mRNA in human brain. Eur. J. Neurosci. 2004, 19:3125-3128.
32. Ding J., et al. RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion. Nat. Neurosci. 2006, 9:832-842.
33. Levitt P., et al. Making the case for a candidate vulnerability gene in schizophrenia: Convergent evidence for regulator of G-protein signaling 4 (RGS4). Biol. Psychiat. 2006, 60:534-537.
34. Hooks S.B., et al. A role of RGS proteins in drug addiction. Biochem. Pharmacol. 2008, 75:76-84.
35. Armbruster B.N., et al. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:5163-5168.
36. Guettier J.M., et al. A chemical-genetic approach to study G protein regulation of β cell function in vivo. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:19197-19202.
37. Del Prato S., et al. Phasic insulin release and metabolic regulation in type 2 diabetes. Diabetes 2002, 51(Suppl. 1):S109-S116.
38. Nesher R., Cerasi E. Modeling phasic insulin release: immediate and time-dependent effects of glucose. Diabetes 2002, 51(Suppl. 1):S53-S59.
39. De Koning E.J., et al. Preservation of β-cell function by targeting β-cell mass. Trends Pharmacol. Sci. 2008, 29:218-227.
40. Lingohr M.K., et al. Specific regulation of IRS-2 expression by glucose in rat primary pancreatic islet β-cells. J. Biol. Chem. 2006, 281:15884-15892.
41. Niessen M. On the role of IRS2 in the regulation of functional β-cell mass. Arch. Physiol. Biochem. 2006, 112:65-73.
42. White M.F. Regulating insulin signaling and β-cell function through IRS proteins. Can. J. Physiol. Pharmacol. 2006, 84:725-737.
43. 11-mediated signaling pathway is critical for autocrine potentiation of insulin secretion in mice. J. Clin. Invest. 2010, 120:2184-2193.
44. Healy J.A., et al. Cholinergic augmentation of insulin release requires ankyrin-B. Sci. Signal. 2010, 3:ra19.
45. Sumara G., et al. Regulation of PKD by the MAPK p38δ in insulin secretion and glucose homeostasis. Cell 2009, 136:235-248.
46. Oancea E., et al. Mechanism of persistent protein kinase D1 translocation and activation. Dev. Cell 2003, 4:561-574.
47. Johnson D.E., et al. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes 2005, 54:1552-1558.
48. Rajagopal S., et al. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat. Rev. Drug Discov. 2010, 9:373-386.
49. 3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:9440-9445.